Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma

Publication Date: March 1, 2021

Key Points

Key Points

  • Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
  • NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.

Treatment

...reatment

...iotherapy: For Patients with Stage II to IVA Naso...

...ion 1.1For all nasopharyngeal carcinom...

...endation 1.2For all NPC patients, both sequent...

...commendation 1.3For all NPC patients, a prescr...

...ndation 1.4For all NPC patients, gross tumor volu...

...commendation 1.5For NPC patients who...

...ation 1.6The delineation of elective nodal...


...herapy Sequence...

...ecommendation 2.1For T2N0 (AJCC 8th)...

...mendation 2.2For T1-2N1 (AJCC 8th) NPC patient...

...tion 2.3For Stage III–IVA (except T3N0...

...2.4For Stage III–IVA (except T3N0...

...commendation 2.5For T3N0 (AJCC 8th) NPC...


Concurrent Chemother...

Recommendation 3.1For all NPC patients witho...

...mendation 3.2For all NPC patients without contrain...

...3.3For NPC patients with a contraindication to...

...n 3.4For NPC patients with a contr...


...ction Chemotherapy

...ecommendation 4.1For all NPC patients r...

...dation 4.2For NPC patients receivi...

...4.3For NPC patients receiving induction c...


...t Chemotherapy...

...5.1For all NPC patients receiving adjuvant chem...

...ndation 5.2For all NPC patients recei...

...ion 5.3For all NPC patients receiving adjuvant che...


...ure 1. Stage II to IVA Nasopharyngeal...